Frederick Beddingfield, III, MD, PhD, FAAD

Executive Chairman Phio Pharmaceuticals, Corp.

Dr. Brubaker is a recognized pharmaceutical drug and medical device development expert with 25+ years of experience with an emphasis in ophthalmic, otic, and respiratory disease areas. He has demonstrated sustained high performance throughout his career. Progressing from scientific/technical subject matter expert to technical and project.

Qiang (John) Wang, PhD, DVM

Associate Vice President, External Innovation, Immunology

Qiang (John) Wang has been an Associate Vice President and Head of Immunology External Innovation at Eli Lilly since December 2018. Since joining Eli Lilly, John has identified and brought in numerous external innovation opportunities leading to several significant transactions including a $1.1 billion acquisition of Dermira.

George D. Yancopoulos, MD, PhD

Co-Founder, President, & Chief Scientific Officer Regeneron

George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer, has built Regeneron for nearly 35 years alongside President and Chief Executive Officer Leonard S. Schleifer, M.D., Ph.D. Regeneron invents life-transforming medicines for people with serious diseases. Its unique ability to repeatedly and consistently translate science .

Nick Williams, MPharm, PhD

Chief Corporate Development Officer Galderma

Nick is a Partner at Medicxi and is a Board Director of Vaderis, Versanis, Alderaan Biotechnology and Yukin Therapeutics. Prior to joining Medicxi, Nick co-founded a start-up urology company and worked in various business development and consulting roles for biotechnology companies.

Todd Krueger

President & Chief Executive Officer AOBiome Therapeutics, Inc

Todd Krueger is the Chief Executive Officer, President and a Director of AOBiome Therapeutics. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015. Mr. Krueger graduated from Phi Beta Kappa from Northwestern University with a Bachelor of Economics and earned his MBA from the Kellogg School of Management.

Jesper J. Lange

Chief Executive Officer MC2 Therapeutics A/S

Jesper J. Lange holds a Master of Law (LLM) degree from Columbia University Law School in New York and is co-founder of MC2 Therapeutics. He joined the company from his position as M&A partner in a major Danish law firm.

Hervé Hoppenot

Chairman, President and Chief Executive Officer Incyte

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015.

Nichola Eiovits

Managing Partner Olive Tree Capital Therapeutics

As Managing Partner at Olive Tree Capital, Nichola leads stage and sector agnostic equity investments, primarily in technology and life sciences companies. Nichola led his first technology startup company through acquisition, and currently serves on the multiple boards.